HBMN:SWX
HBM Healthcare Investments AG
233,00 CHF
arrow_upward
+0,43%(+1,00) 1D
30. 4., 14:00:21 GMT+2 · CHF
search
Všechny symboly
1D
5D
1M
6M
YTD
1R
5R
MAX
| Symbol | Cena | Změna | Změna (%) |
|---|
insights_autoGenerování hlavních statistik pro HBMN…
Otevřít
231,50 CHF
Max.
234,00 CHF
Min.
228,00 CHF
Trž. kap.
1,57 mld.
Prům. obj.
6,47 tis.
Objem
1,16 tis.
Dividenda
3,22 %
Čtvrtletní dividenda
1,88 CHF
Datum ex dividenda
2. 7. 2025
Ukazatel P/E
6,49
52týd. max.
245,50 CHF
52týd. min.
157,40 CHF
EPS
35,93 CHF
Akcie v oběhu
6,74 mil.
Zpravodajské články
Ze zdrojů na internetu
StockStory
·
před 3 minutami
Garrett Motion’s (NASDAQ:GTX) Q1 CY2026: Strong Sales, Stock Soars
MarketBeat
·
před 3 minutami
Eos Energy Enterprises (NASDAQ:EOSE) Rating Increased to Hold at Zacks Research
The Motley Fool
·
před 6 minutami
Meet the Unstoppable Vanguard ETF Beating the S&P 500, the Nasdaq-100, and the Dow Jones in 2026
FOREX.com
·
před 8 minutami
S&P 500 forecast: What now after for US stock markets?
Profil
HBM Healthcare Investments is a publicly traded Swiss investment and venture capital firm focusing on emerging technologies in the global healthcare sector. Within healthcare their focus is predominantly in biotechnology, medical technology, diagnostics, therapeutics and digital health.
A 2022 article in Swiss daily Luzerner Zeitung profiled HBM and interviewed its CEO, and described the company’s investment strategy as focused on early-stage but post-seed round opportunities.
Founded in July 2001 as HBM Bioventures AG by former Roche Chief Financial Officer Henri B. Meier who was its first Chairperson of the Board. A Handelszeitung article from 2020 described Meier's goal when founding the company as to profit from the "thesis" that from the 2000s onwards "Big Pharma is doing less and less research and development itself and is instead acquiring promising biotech companies" In an analysis of how HBM was put together, Swiss magazine Finanz und Wirtschaft described how he was able to raise almost 500 million Swiss Francs for the company launch. HBM is based in Zug and managed by HBM Partners. HBM acquired rival Swiss VC International BM Biomedicine in 2005. Wikipedia
Informace o HBM Healthcare Investments AG
Generální ředitel-
Zaměstnanci-
Založeno12. 7. 2001
ÚstředíZug, Zug, Švýcarsko
Odvětví-
Obsah od AI může obsahovat chyby. Další informace